Zydus receives tentative approval from the USFDA for Canagliflozin Tablets

Zydus receives tentative approval from the USFDA for Canagliflozin Tablets Ahmedabad, India, 15 February, 2023 Zydus Lifesciences Limited (including its subsidiaries/affiliates hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) to market Canagliflozin Tablets, 100 mg and 300 mg (USRLD: Invokana® Tablets). Canagliflozin Tablet is a sodium -glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya. Canagliflozin Tablets had annual sales of USD 660 mn in the United States (IQVIA MAT Dec. 2022). The group now has 341 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04. (*as of 31st December 2022) ***

The release as fetched from its publisher. zyduslife.com ↗